Anebulo Pharmaceuticals, Inc. (ANEB) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/18/2026
- Wall Street sinks on bets Fed will hike rates this year
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Oil rises 1% on US-Iran deal doubts; IEA warns of supply glut
- Intel stock gains premarket after 18A-P chip process enters early production
- The top stocks to own for a major structural shift in the U.S. economy
- After-Hours Stock Movers: SWBI, SB, LPA, STLD, SPCX
- UniQure, Aehr Test Systems surge premarket; Snap, Leidos fall
- SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fall
- Micron, Nebius surge premarket; Traws Pharma tumbles
- After-Hours Stock Movers: ADBE, MRVL, RH, RKLB, RDW, SPCE, ASTS
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates
February 10, 2023 8:38 AM ESTAUSTIN, Texas--(BUSINESS WIRE)-- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the Company or Anebulo), today announced financial results for the three months ended December 31, 2022 and recent updates.
Second Quarter Fiscal Year 2023 and Subsequent Highlights:
Completed dosing its randomized, double-blind, placebo-controlled Phase 2 trial evaluating ANEB-001s potential in treating acute cannabinoid intoxication (ACI). Preliminary data showed that a single 10 mg oral dose of ANEB-001 reduced key symptoms... More